195 related articles for article (PubMed ID: 28976206)
21. Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.
Park JG; Park SY; Lee HW
World J Gastroenterol; 2015 Feb; 21(8):2568-72. PubMed ID: 25741170
[TBL] [Abstract][Full Text] [Related]
22. Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.
Lorenzin D; Pravisani R; Leo CA; Bugiantella W; Soardo G; Carnelutti A; Umberto B; Risaliti A
Cancer Biother Radiopharm; 2016 Mar; 31(2):65-9. PubMed ID: 26986817
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
24. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know.
Kim YH; Kim DY
Oncology; 2013; 84 Suppl 1():34-9. PubMed ID: 23428856
[TBL] [Abstract][Full Text] [Related]
25. Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).
Kudo M; Arizumi T
Oncology; 2017; 93 Suppl 1():127-134. PubMed ID: 29258086
[TBL] [Abstract][Full Text] [Related]
26. NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with
Venerito M; Pech M; Canbay A; Donghia R; Guerra V; Chatellier G; Pereira H; Gandhi M; Malfertheiner P; Chow PKH; Vilgrain V; Ricke J; Leandro G
J Nucl Med; 2020 Dec; 61(12):1736-1742. PubMed ID: 32358087
[TBL] [Abstract][Full Text] [Related]
27. Poly(lactide-co-glycolide) microspheres for MRI-monitored transcatheter delivery of sorafenib to liver tumors.
Chen J; Sheu AY; Li W; Zhang Z; Kim DH; Lewandowski RJ; Omary RA; Shea LD; Larson AC
J Control Release; 2014 Jun; 184():10-7. PubMed ID: 24727059
[TBL] [Abstract][Full Text] [Related]
28. Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis.
Cho YY; Lee M; Kim HC; Chung JW; Kim YH; Gwak GY; Bae SH; Kim do Y; Heo J; Kim YJ
PLoS One; 2016; 11(5):e0154986. PubMed ID: 27149067
[TBL] [Abstract][Full Text] [Related]
29. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions.
Duran R; Chapiro J; Schernthaner RE; Geschwind JF
Br J Radiol; 2015 Aug; 88(1052):20140564. PubMed ID: 25978585
[TBL] [Abstract][Full Text] [Related]
30. [Advanced hepatocellular carcinoma: importance of clinical trials].
Aedo V; Cristina V; Raymond E; Faivre S
Rev Med Suisse; 2015 May; 11(475):1149-51. PubMed ID: 26152091
[TBL] [Abstract][Full Text] [Related]
31. Refining sorafenib therapy: lessons from clinical practice.
Bolondi L; Craxi A; Trevisani F; Daniele B; Di Costanzo GG; Fagiuoli S; Cammà C; Bruzzi P; Danesi R; Spandonaro F; Boni C; Santoro A; Colombo M
Future Oncol; 2015; 11(3):449-65. PubMed ID: 25360997
[TBL] [Abstract][Full Text] [Related]
32. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study.
Palmer DH; Hawkins NS; Vilgrain V; Pereira H; Chatellier G; Ross PJ
Future Oncol; 2020 Jan; 16(1):4315-4325. PubMed ID: 31797680
[No Abstract] [Full Text] [Related]
33. A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials.
Pollock RF; Brennan VK; Shergill S; Colaone F
Expert Rev Anticancer Ther; 2021 Mar; 21(3):341-349. PubMed ID: 33131346
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib plus cisplatin for hepatocellular carcinoma.
Brower V
Lancet Oncol; 2016 Oct; 17(10):e424. PubMed ID: 27617663
[No Abstract] [Full Text] [Related]
35. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
Shiozawa K; Watanabe M; Ikehara T; Kogame M; Matsui T; Okano N; Kikuchi Y; Nagai H; Ishii K; Makino H; Igarashi Y; Sumino Y
Hepatogastroenterology; 2014 Jun; 61(132):885-91. PubMed ID: 26158136
[TBL] [Abstract][Full Text] [Related]
37. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
Ricke J; Bulla K; Kolligs F; Peck-Radosavljevic M; Reimer P; Sangro B; Schott E; Schütte K; Verslype C; Walecki J; Malfertheiner P;
Liver Int; 2015 Feb; 35(2):620-6. PubMed ID: 24930619
[TBL] [Abstract][Full Text] [Related]
38. Combination of intra-arterial therapies and sorafenib: is there a clinical benefit?
Chapiro J; Duran R; Geschwind JF
Radiol Med; 2014 Jul; 119(7):476-82. PubMed ID: 24894921
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
40. Education and imaging. Hepatology: Complete regression of locally advanced hepatocellular carcinoma following Sorafenib monotherapy.
Kumar S
J Gastroenterol Hepatol; 2015 Mar; 30(3):438. PubMed ID: 25707790
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
